Posted by Michael Wonder on 20 Sep 2022
Stryker receives FDA clearance for OptaBlate bone tumour ablation system
20 September 2022 - Stryker's first bone tumour ablation system with patented microinfusion technology offers a reliable solution for people living with painful metastatic tumours.
Stryker announced today that its OptaBlate bone tumour ablation system (OptaBlate) received 510(k) clearance from the US FDA
